Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Chi Wong who wrote (3005)	4/12/2000 1:06:00 PM
From: Marty R	Respond to of 5665

<<"Soon" is a four letter word for many longs that spells 'frustration'.>> I couldn't agree more. I'm curious about your comment re: McAmmant indicating more than 1 partnership. Can you provide a source on this. Not to imply anything. But, the continual speculation without substinative announcements is as you say ... frustrating. Regards

To: Chi Wong who wrote (3005)	4/12/2000 1:16:00 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

The partnerships will occur in time, but let's look at what we know will happen. Results on the Prostate Drug that's been spoken about for some time will be presented at two major conferences. This would not happen if they were not impressive. The Phase 1/2 Trial will go to a Multi-Dose Protocol, with this we can expect a substantial Milestone Payment. The BCHE Partnership will be renewed before its scheduled to end in July. From all we've heard BCHE is delighted by results, they'd have to return everything they've gained if the Partnership wasn't renewed. The IND will be filed on N901-DM1 whether a Partnership is announced or not, Phase 1 Trails will proceed as well. The point is, their's substantial good news that we know will happen during the remainder of the year. Add to that the good news we also expect, and the remainder of the year could be truly great. To me the biggest news will not be partnerships or new drugs, it will be Efficacy, and that word could come almost any time. After Efficacy, we could hear about remissions, total remissions and perhaps the word CURE will even be used, it could all happen this year. Right now with no news, we're moving down with the Nasdaq and Biotech Indexes in general. Once news comes we should certainly break out, and perhaps we'll help to get at least the Biotech Index going in the right direction. Gary